BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Wall Street Zen

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a note issued to investors on Thursday.

A number of other research firms also recently commented on BCRX. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Needham & Company LLC boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. JMP Securities reiterated a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded up $0.20 during midday trading on Thursday, reaching $10.79. 4,279,777 shares of the company were exchanged, compared to its average volume of 3,031,390. BioCryst Pharmaceuticals has a 12 month low of $5.92 and a 12 month high of $11.11. The company has a market cap of $2.26 billion, a P/E ratio of -17.69 and a beta of 1.08. The company's 50 day moving average price is $8.50 and its two-hundred day moving average price is $8.09.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter last year, the business earned $0.28 EPS. The company's quarterly revenue was up 40.8% compared to the same quarter last year. As a group, sell-side analysts predict that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Headlands Technologies LLC purchased a new position in shares of BioCryst Pharmaceuticals in the first quarter worth approximately $32,000. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $33,000. GAMMA Investing LLC grew its position in BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 5,449 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $46,000. Finally, R Squared Ltd purchased a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $48,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.